Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment

AIMS: This post hoc assessment evaluated the efficacy and safety of once‐daily, prandial glucagon‐like peptide‐1 receptor agonist lixisenatide in patients with type 2 diabetes (T2D) and normal renal function (estimated glomerular filtration rate ≥90 mL/min), or mild (60‐89 mL/min) or moderate (30‐59...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Obes Metab
Autors principals: Hanefeld, Markolf, Arteaga, Juan M., Leiter, Lawrence A., Marchesini, Giulio, Nikonova, Elena, Shestakova, Marina, Stager, William, Gómez‐Huelgas, Ricardo
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2017
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5655920/
https://ncbi.nlm.nih.gov/pubmed/28449324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12986
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars